ArticlePulmonary therapy2026
Estimation of Public Health Impact with Use of Nirsevimab During the 2024-2025 RSV Season in the USA: a Modeling Study.
Article in Pulmonary therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Regional inequality in infant RSV morbidity and mortality burden in the era of expanded RSV passive immunisation: a global projection modelling study.EClinicalMedicine · 2026Article
- Breaking the sound barrier: global monoclonal antibody pharmacoequity.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRespiratory syncytial virus (RSV) is a leading cause of medically attended lower respiratory tract disease (MA-LRTD) and hospitalization among infants in the USA. With the introduction in 2023 of nirsevimab, a long-acting monoclonal antibody for infant RSV prevention, early data on observed uptake provides an opportunity to quantify its public health impact. We hypothesized that the observed nirsevimab immunization coverage rate during the 2024-2025 RSV season substantially reduced the clinical burden of RSV relative to the pre-2023 standard of practice (SoP) and that increasing coverage levels comparable with other routine pediatric immunizations would yield substantial reductions in RSV-associated outcomes.
methodsWe employed a previously published and validated static decision model to estimate RSV MA-LRTDs under multiple nirsevimab coverage scenarios. The analysis compared projected RSV burden under the pre-2023 SoP where only high-risk infants receive palivizumab with scenarios reflecting the observed national nirsevimab coverage during the 2024-2025 RSV season (44.7%) and higher hypothetical coverage levels up to universal, 100% coverage among infants not eligible for palivizumab. Outcomes included RSV-related hospitalizations, emergency room (ER) visits, primary care (PC) visits, and RSV-associated deaths. Number needed to immunize (NNI) values were also calculated relative to the pre-2023 SoP.
resultsUnder the pre-2023 SoP, the model estimated 523,594 RSV MA-LRTDs among infants during the 2024-2025 RSV season. At the observed nirsevimab coverage of 44.7%, 204,306 RSV MA-LRTDs were averted, including 18,765 hospitalizations (42% reduction), 49,570 ER visits (39%), and 135,942 PC visits (39%). Increasing coverage to 80.4%-aligned with uptake for other routine infant vaccines-was projected to avert 364,204 RSV MA-LRTDs (159,898 additional cases prevented beyond the 44.7% scenario), including 32,404 hospitalizations (73% reduction). Universal coverage (100%) yielded the greatest benefit, averting 451,991 cases (86% reduction) and 39,891 hospitalizations. The number needed to immunize (NNI) was 9 for one MA-LRTD averted, 91 for one hospitalization, and 34 for one ER visit.
conclusionsNirsevimab has already achieved substantial reductions in RSV-associated clinical burden at current national coverage levels. Modeled increases in coverage demonstrate large, incremental public health gains with complete universal immunization yielding up to an 86% reduction in RSV MA-LRTDs. These findings highlight the importance of implementing strategies that enhance access, reduce inequities, and support higher, sustained coverage to maximize population-level benefits of RSV prophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.